GS-8670
/ Gilead
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 16, 2025
GS-8670: An Intestinally Targeted Farnesoid X Receptor Agonist Restoring Barrier Integrity and Demonstrating Robust Efficacy in Colitis Models
(ECCO-IBD 2026)
- "Conclusion GS-8670 demonstrated robust efficacy in two distinct colitis models and promoted epithelial barrier restoration both in vivo and in vitro. These findings support GS-8670 as a promising oral therapy for IBD, complementing current anti-inflammatory approaches by directly targeting barrier integrity."
Clinical • Crohn's disease • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis • IL10
1 to 1
Of
1
Go to page
1